SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed · Phase 3

Conditions studied: Metastatic Breast Cancer

In brief

The purpose of this study is to demonstrate that SYD985 \[(vic-)trastuzumab duocarmazine\] is superior to physician's choice in prolonging progression free survival.

Key facts

Study ID
NCT03262935
Run by
Byondis B.V.
People needed
437
Starts
2017-12-15
Expected to finish
2022-06-30
Last updated by the study team
2023-10-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.